Novo owner backs Swiss biotech company Asceneuron in $100 million round
Swiss biotech company Asceneuron said Tuesday it has raised $100 million from investors including controlling shareholder Wegovy maker Novo Nordisk to fund clinical development of its drug to treat Alzheimer’s disease.
ПОПУЛЯРНЫЕ ПОСТЫ
UK sets new climate target for 2035
Ноябрь 13, 2024
Children go back to school after Valencia floods
Ноябрь 13, 2024
Researchers document huge decline in African elephants
Ноябрь 13, 2024
Mission: Impossible 8 title revealed
Ноябрь 13, 2024
ПОДПИСЫВАЙТЕСЬ НА НАС
ПРЯМАЯ ТРАНСЛЯЦИЯ